ABT vs NYC · P/E 25, rev $44.33B vs $23.1M cap
Abbott Laboratories (ABT) versus New York City REIT Inc (NYC) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
New York City REIT Inc (NYC) is a real estate services company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported NYC revenue for 2024-12-31 was $0. Net income was -$140.6M. NYC currently screens at market cap $23.1M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. NYC currently screens at market cap $23.1M.
Not investment advice. Open the ABT and NYC stock pages for the full models.
Not investment advice.